The Ipilimumab (Yervoy) Results – A Failure that Should Not Have Been A Failure
Last October at the European Cancer Congress 2013 there was a release of data from a phase 3 study of Ipilimumab (CA 184-043) that showed that it might be effective in treating castration-resistant prostate cancer [...]
A Correction of A Prior Post – How About Entering the Prostvac-VF Trail and Then Have Provenge?
On March 4th I wrote a post which included a suggestion that combining Provenge and the clinical trial of Prostvac-VF might provide an interesting one-two punch against advanced prostate cancer. In the post I suggested [...]
Sorting Out Prostate Cancers that Are Resistant to Enzalutamide (Xtandi)
Over the last several years’ prostate cancer treatment options for men with advanced prostate cancer has gone from rags to riches. We now have multiple options for treatment and there is every indication that the [...]
Now Available: Teleconference about Bone Health and Advanced Prostate Cancer
Today, Malecare posted our latest teleconference with Dr. Neal Shore, M.D. The conference, which was recorded last week, is about Bone Health and Prostate Cancer. It discusses the importance of maintaining healthy bones and methods [...]
Are You Willing to Trade some of Your Survival Time and Increase Your Risk for Bone Complications to Decrease Your Risk of Developing Bone Metastases?
Would you be willing to trade off some survival time to lower your risk of developing bone metastases (BM)? Well, men in the UK and Sweden are willing. Men from the UK and Sweden with [...]
Impact of Prior Abiraterone Acetate (Zytiga) on Subsequent Activity of Docetaxel (Chemotherapy) in Men with Metastatic Castration-Resistant Prostate Cancer
The explosion of new therapies for men with metastatic castration resistant prostate cancer (mCRPC) raises serious questions about the optimal sequencing of these new treatments as well as whether cross-resistance occurs between these drugs. It [...]